New Drugs Yield Limited Benefit; Big Jump in Drug Prices; AI Boost for Mammo Results News, features, and commentary about cancer-related issues Mar 01, 2024
PROs for Cutaneous Chronic GVHD After Transplant Tied to Disease Severity, Mortality Baseline QOL, symptom burden could inform risk stratification, treatment decisions Feb 28, 2024
Amy Schumer's Diagnosis; FDA Yanks Cancer Drug; Nursing Student Murdered Health news and commentary from around the Web gathered by 51˶ staff Feb 26, 2024
Transforming Shots Into Pills; 'Tip of the Iceberg' for TILs? Food Additives Warning News, features, and commentary about cancer-related issues Feb 23, 2024
Male Fertility Problems in the Family Linked to Cancer Risk Low sperm levels were tied to specific cancers in family members Feb 22, 2024
Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma No PFS benefit from adding the monoclonal antibody to standard therapy Feb 20, 2024
For Kids With Sickle Cell Disease Prescribed Opioids, No Patterns of Misuse Emerged Number of vaso-occlusive crises tied to days' supply Feb 19, 2024
Rush to Publish? Medicare Drug Plan Lawsuit Quashed; Activity Curbs Cancer Pain News, features, and commentary about cancer-related issues Feb 16, 2024
Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML But it's unlikely stem cell transplants will ever be large-scale cure for HIV, says expert Feb 14, 2024
FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia Complete response rate of 86%, median event-free survival approaching 4 years with crenolanib Feb 13, 2024
No Relief From Drug Shortages; New Lymphedema Guideline; A 'Good' Patient No More News, features, and commentary about cancer-related issues Feb 09, 2024
Pulled Myeloma Drug May Have a Role in Treating the Disease After All Belantamab mafodotin boosts PFS by nearly 2 years when combined with bortezomib, dexamethasone Feb 07, 2024
All-Oral Therapy Promising in Higher-Risk MDS, CMML In small trial, overall response rate was 95% Feb 05, 2024
Camp Lejeune Water Contamination Tied to a Range of Cancers, CDC Study Says Health risks now more firmly established, but study falls short of being definitive Feb 01, 2024
Most Immunocompromised Patients Clear Omicron Infections B-cell malignancies, B-cell treatments associated with longer duration of infection Jan 30, 2024
When a Revolutionary Cancer Treatment Causes Cancer The potential benefits of CAR T-cell therapies still far outweigh the risks Jan 27, 2024
CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning Post-treatment cases grow to 22 since products' initial approvals Jan 24, 2024
FDA Calls for New Boxed Warning on All CAR-T Products Most serious warning would alert patients, providers on potential risk for secondary malignancies Jan 23, 2024
Gene Therapy for Sickle Cell Disease Likely Cost-Effective if Under $2 Million Lifetime reduction in acute pain episodes should offset high upfront costs of the therapy Jan 22, 2024
Two Million Cancers; Casgevy OK'd for Thalassemia; Rectal Exams and Prostate Cancer News, features, and commentary about cancer-related issues Jan 19, 2024
Kate Middleton Hospitalized; Sen. Paul Urges Prison for Fauci; COVID Back in Class Health news and commentary from around the Web gathered by 51˶ staff Jan 17, 2024
Carvedilol No Help in Preventing Heart Failure in Childhood Cancer Survivors While safe, the results do not support use of the drug in anthracycline-exposed survivors Jan 10, 2024
Direct Thrombin Inhibitor Shows Benefit for Progressing Stroke Urgent anticoagulation with argatroban shows no bleeding downside in EASE trial Jan 09, 2024
Gene Therapy for Hemophilia Becomes a Reality Uptake of new options for hemophilia A and B has been a bit slow Dec 29, 2023
Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL Approach could allow for a response-adapted reduction of CHOP Dec 27, 2023 video
Longer Letermovir Prophylaxis Reduced Risk of Cytomegalovirus Infection After HSCT Randomized study showed extending prophylaxis from 100 to 200 days was effective and safe Dec 27, 2023
Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma Our panel of experts discuss 3-year findings from the phase II ELARA study Dec 26, 2023 video
Mammo Responsibility Ups Screening; Opioids for Cancer Pain? Ignored Signs of CRC News, features, and commentary about cancer-related issues Dec 21, 2023
JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma Phase II findings on golidocitinib will form the basis of an accelerated approval application Dec 15, 2023
Hematocrit Stabilized in Polycythemia Vera Treated With Novel Hepcidin Mimetic Rusfertide maintained hematocrit Dec 15, 2023
Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma Will results revive ibrutinib role in MCL following withdrawal of accelerated approval? Dec 13, 2023
'Half-Matched' BMTs Effective in Severe Sickle Cell Disease High survival rates observed in patients not normally suitable for transplant Dec 13, 2023
Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder 24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial Dec 13, 2023
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis Combos with navitoclax or pelabresib led to more patients achieving reductions Dec 12, 2023
Axatilimab Shows Efficacy in Recurrent/Refractory GVHD Highest overall response rate and least toxicity seen with lowest dose Dec 11, 2023
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease This landmark event brings up broader considerations and implications for other diseases Dec 11, 2023
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
